✦ LIBER ✦

Progress and stiff challenges in understanding the role of GAD-antibodies in stiff-person syndrome

✍ Scribed by Dalakas, Marinos C.

Book ID: 122649931
Publisher: Elsevier Science
Year: 2013
Tongue: English
Weight: 424 KB
Volume: 247
Category: Article
ISSN: 0014-4886
DOI: 10.1016/j.expneurol.2013.02.010

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Pathological findings in a case of stiff

Pathological findings in a case of stiff person syndrome with anti-GAD antibodies

✍ Jonathan Witherick; J. Robin Highley; Marios Hadjivassiliou 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 1023 KB

Posterior cortical atrophy (PCA) represents a degenerative disorder characterized by the development of higherorder visual deficit. 1 PCA may result from heterogeneous pathologies that make up tauopathies. An increasing number of mutations in the tau gene (microtubule-associated protein tau [MAPT])

The role of IVIg in the treatment of pat

The role of IVIg in the treatment of patients with stiff person syndrome and other neurological diseases associated with anti-GAD antibodies

✍ Marinos C. Dalakas 📂 Article 📅 2005 🏛 Springer 🌐 English ⚖ 294 KB

Pathological evidence of encephalomyelit

Pathological evidence of encephalomyelitis in the stiff man syndrome with anti-GAD antibodies

✍ Jason D. Warren; Grace Scott; Peter C. Blumbergs; Philip D. Thompson 📂 Article 📅 2002 🏛 Elsevier Science 🌐 English ⚖ 202 KB

A therapeutic trial of milacemide in myo

A therapeutic trial of milacemide in myoclonus and the stiff-person syndrome

✍ P. Brown; P. D. Thompson; J. C. Rothwell; B. L. Day; Prof. C. D. Marsden 📂 Article 📅 1991 🏛 John Wiley and Sons 🌐 English ⚖ 269 KB 👁 1 views

We investigated the therapeutic effects of milacemide in seven patients with myoclonus and three patients with the stiff-person syndrome in an open-label trial. Milacemide was initiated at 800 mg/day and was gradually increased to a maximum dosage of 2,400 mg/day. No significant improvement occurred

Characterization of CD4+ T cells specifi

Characterization of CD4+ T cells specific for glutamic acid decarboxylase (GAD65) and proinsulin in a patient with stiff-person syndrome but without type 1 diabetes

✍ Arno Hänninen; Merja Soilu-Hänninen; Christiane S. Hampe; Angie Deptula; Kelly G 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 287 KB

Qualitative and quantitative evidence of

Qualitative and quantitative evidence of anti-glutamic acid decarboxylase-specific intrathecal antibody synthesis in patients with stiff person syndrome

✍ S. Jarius; O. Stich; J. Speck; Ch. Rasiah; B. Wildemann; H.M. Meinck; S. Rauer 📂 Article 📅 2010 🏛 Elsevier Science 🌐 English ⚖ 656 KB